Continuous Local Anesthetic Wound Infiltration Protocol
Continuous local wound infusion catheters should be placed in the pre-peritoneal or subcutaneous space above the fascia at the end of surgery, with 0.2% ropivacaine infused at 6 ml/hour for 48 hours to provide effective postoperative analgesia. 1, 2
Catheter Placement Technique
Positioning and Insertion
- Insert a multi-hole, 20-gauge catheter percutaneously above the fascia in the pre-peritoneal or subcutaneous space at the end of the surgical procedure 2
- The catheter should be positioned to cover the entire length of the surgical wound 2
- Aspirate the catheter prior to injection to avoid intravascular administration 1
Initial Bolus Dose
- Administer an initial bolus of 10 ml of 0.2% ropivacaine through the catheter immediately after placement 2
- This provides immediate local anesthetic effect before starting the continuous infusion 2
Continuous Infusion Protocol
Anesthetic Agent and Concentration
- Use 0.2% ropivacaine as the primary agent for continuous wound infiltration 2
- Ropivacaine is preferred over bupivacaine due to lower systemic toxicity, allowing higher doses 3
- The FDA label supports ropivacaine for local infiltration at concentrations up to 5 mg/mL (0.5%), though 0.2% is most commonly used for continuous infusion 4
Infusion Rate and Duration
- Initiate continuous infusion at 6 ml/hour of 0.2% ropivacaine 2
- Continue infusion for 48 hours postoperatively 2
- This provides total delivery of approximately 288 ml over 48 hours (12 mg/hour or 576 mg total) 2
Maximum Dosing Guidelines
Adults
- For wound infiltration: maximum 1 ml/kg of 0.25% bupivacaine (2.5 mg/kg) or 1.5 ml/kg of 0.2% ropivacaine (3 mg/kg) as single-shot infiltration 1
- For continuous infusion with ropivacaine: the 6 ml/hour rate at 0.2% concentration (12 mg/hour) remains well below toxic thresholds when distributed over 48 hours 2
Pediatric Patients
- Maximum 1 ml/kg of 0.25% bupivacaine (2.5 mg/kg) for single-shot wound infiltration 1
- Maximum 1.5 ml/kg of 0.2% ropivacaine (3 mg/kg) for single-shot wound infiltration 1
Safety Monitoring and Precautions
Toxicity Prevention
- Use the lowest effective dose to minimize risk of local anesthetic systemic toxicity (LAST) 1
- Aspirate before each injection or bolus to prevent intravascular administration 1
- Continuously monitor patients for early signs of toxicity: perioral numbness, metallic taste, tinnitus, confusion, or seizures 1
Infection Risk
- Pre-peritoneal catheters are not associated with increased surgical site infection risk 1
- However, catheters retained in situ do carry theoretical infection risk with prolonged use beyond 48-72 hours 5
Catheter Removal Planning
- Establish a planned removal process with institution of appropriate alternative analgesia before discontinuing the catheter 1
- Transition to oral or parenteral analgesics should begin before catheter removal to prevent pain breakthrough 1
Clinical Efficacy Outcomes
Pain Reduction
- Continuous wound infusion significantly decreases visual analog pain scores at rest and with activity at 6,12,24, and 48 hours postoperatively 1
- Pain scores at 12 hours are significantly lower compared to patient-controlled analgesia (PCA) alone 1
Opioid-Sparing Effect
- Consistently reduces total opioid consumption and rescue analgesic requirements 1, 2
- This technique should be incorporated as part of multimodal analgesia rather than sole analgesic strategy 1
Functional Recovery
- Patients experience improved ambulation time and earlier return of intestinal function 1, 2
- Respiratory function shows trends toward improvement, though not always statistically significant 2
Common Pitfalls to Avoid
- Do not place catheters in patients with active surgical site infection or systemic sepsis 1
- Avoid in patients on therapeutic anticoagulation without appropriate risk assessment 1
- Do not exceed maximum dosing limits when combining continuous infusion with other local anesthetic techniques (e.g., TAP blocks, epidurals) 1
- Ensure catheter is secured properly to prevent dislodgement during patient movement 2
- Do not abruptly discontinue infusion without transitioning to alternative analgesia 1